Cancer vaccine therapy using MAGE products

Fumiaki Tanaka, Kouichirou Tahara, Koshi Mimori, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

Abstract

We have treated patients with advanced gastrointestinal cancer using dendritic cells (DCs) and MAGE peptides since 1997 as (Far) Advanced Medicine. The patients have already been given standard therapy such as surgery, chemotherapy and radiation therapy. They also have measurable disease using CT and/or MRI. Considering their situation, the patients who joined the study have poor systemic condition. Here we report the clinical results of our cancer vaccine therapy for 28 patients. Recently, at the ASCO Meeting, a phase II study using MAGE-A3 compound for patients with completely resected lung cancer was reported. The result was quite promising, and now phase III study has been performed all over the world including Japan. Finally, we show some data addressing a future promising plan for a cancer vaccine strategy targeting cancer stem cells or developing new cancer antigens with microarray technologies.

Original languageEnglish
Pages (from-to)379-384
Number of pages6
JournalBiotherapy
Volume22
Issue number6
Publication statusPublished - Nov 1 2008

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tanaka, F., Tahara, K., Mimori, K., Inoue, H., & Mori, M. (2008). Cancer vaccine therapy using MAGE products. Biotherapy, 22(6), 379-384.